Synta And Roche Agree To Co-Develop Anti-Inflammatory Drugs
Deal for Synta’s CRAC channel inhibitor brings $25 million upfront plus potential for $1 billion in milestones.
Deal for Synta’s CRAC channel inhibitor brings $25 million upfront plus potential for $1 billion in milestones.